Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19041345 | 0.83 | MEN1 (0.40) | MEN1KMT2AEPHX1 | |
| Iodide SCHEMBL5453631 | 0.80 | — | — | |
| SCHEMBL27532474 | 0.80 | — | — | |
| SCHEMBL4105241 | 0.77 | — | — | |
| SCHEMBL1275944 | 0.76 | MEN1 (0.44) | MEN1KMT2AEPHX1 | |
| SCHEMBL20315914 | 0.76 | EPHX1 (0.36) | MEN1KMT2AEPHX1 | |
| Hydrochloric Acid SCHEMBL28486558 | 0.75 | — | — | |
| SCHEMBL24018750 | 0.74 | MEN1 (0.33) | MEN1KMT2AEPHX1 | |
| SCHEMBL12562530 | 0.74 | MEN1 (0.33) | MEN1KMT2AEPHX1 | |
| SCHEMBL27299135 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3984997-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-10294215-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-28 | — | — | US | disclosed |
| EP-2800743-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-19 | — | — | US | disclosed |
| US-9732062-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20140163136-A1 | HYDROPHILIC BIOCIDAL COATINGS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013102431-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | MALLE GERARD | 2009-08-06 | — | — | US | disclosed |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | L'OREAL S.A. | 2009-06-04 | — | — | US | disclosed |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | L'OREAL S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | L'OREAL | 2005-06-16 | — | — | US | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | MEN1 1875/4885KMT2A 2484/4885NOS1 4641/4885 |
| US-11505538-B1 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | MEN1 1875/4885KMT2A 2484/4885NOS1 4641/4885 |
| US-20090139537-A1 | HAIR RELAXING COMPOSITION COMPRISING AT LEAST ONE NON-HYDROXIDE IMINE | KRT18, INMT, INHA | MEN1 261/4885KMT2A 322/4885NOS1 166/4885 |
| US-20090194124-A1 | Hair Shaping Kit and Process Comprising at Least One Non-Hydroxide Imine | KRT18, KIT, PRDM7 | MEN1 294/4885KMT2A 555/4885NOS1 591/4885 |
| US-20170298045-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | MEN1 1875/4885KMT2A 2484/4885NOS1 4641/4885 |
| US-20140163136-A1 | HYDROPHILIC BIOCIDAL COATINGS | SCNN1G, FHIT, PARG | MEN1 4201/4885KMT2A 373/4885NOS1 2089/4885 |
| US-20130190287-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | MEN1 1875/4885KMT2A 2484/4885NOS1 4641/4885 |
| US-10294215-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | MEN1 1875/4885KMT2A 2484/4885NOS1 4641/4885 |
| US-20050129645-A1 | Hair shaping composition comprising at least one non-hydroxide imine | KRT18, INHA, H1-5 | MEN1 237/4885KMT2A 949/4885NOS1 681/4885 |
| US-20050136017-A1 | Cosmetic containing an imine reactive with the cystines of keratin fibers via a beta-elimination reaction to produce dehydroalanine and lead to formation of lanthionine in a medium free of polyhydroxylated alkane; guanidine and/or amidine imines such as dimethylguanidine; noncaustic for use on hair, skin | BHMT, KRT18, INMT | MEN1 455/4885KMT2A 665/4885NOS1 200/4885 |
| US-20180177749-A1 | USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER | EPHX1, EPHX2, CYP4X1 | MEN1 4833/4885KMT2A 1854/4885NOS1 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.